利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.071 秒)

    Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
    36.
    发明授权
    Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples 失效
    特异于生物样品中高级糖基化终产物的单克隆抗体

    公开(公告)号：US5892000A

    公开(公告)日：1999-04-06

    申请号：US581724

    申请日：1995-12-29

    申请人： Henry W. Founds ,  Homayoun Sadeghi

    发明人： Henry W. Founds ,  Homayoun Sadeghi

    IPC分类号： G01N33/577 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61M1/38 ,  A61P43/00 ,  C07K16/18 ,  C07K16/46 ,  C12N5/10 ,  C12N5/18 ,  C12N5/20 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/564 ,  G01N33/68 ,  G01N33/72 ,  G01N33/92 ,  C07K16/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  C07K2317/24 ,  Y10S435/975

    摘要： The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibodies selected from the group consisting of 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, 2G6 as produced by hydridoma 2G6, deposited with the American Type Culture Collection (ATCC) on Dec. 19, 1995, and assigned Accession Number HB 12008, and BH4 as produced by hydridoma BH4, deposited with the American Type Culture Collection (ATCC) on Dec. 29, 1995, and assigned Accession Number HB 12010.

    摘要翻译： 本发明涉及在体内形成的晚期糖基化终产物的单克隆抗体和与体外形成的晚期糖基化终产物交叉反应的单克隆抗体以及基于其的诊断和治疗方法。 更具体地，本发明涉及与体内产生的高级糖基化终产物（AGEs）反应的单克隆抗体或其抗原结合片段，所述单克隆抗体或其抗原结合片段表现出选自以下的单克隆抗体的免疫学结合特征： 由美国典型培养物保藏中心（ATCC）保藏的杂交瘤4G9产生的由4G9生产的组合，并且分配于12月19日保藏于美国典型培养物保藏中心（ATCC）的由Hydridoma 2G6生产的保藏号CRL 11626,2GP， 1995年12月29日，保藏于美国典型培养物保藏中心（ATCC）的Hydridoma BH4生产，并分配了登录号HB12008和BH4，并分配了登录号HB 12010。

    Therapeutic methods and pharmaceutical compositions
    37.
    发明授权
    Therapeutic methods and pharmaceutical compositions 失效
    治疗方法和药物组合物

    公开(公告)号：US5766590A

    公开(公告)日：1998-06-16

    申请号：US483184

    申请日：1995-06-07

    申请人： Henry W. Founds ,  Homayoun Sadeghi

    发明人： Henry W. Founds ,  Homayoun Sadeghi

    IPC分类号： A61K38/00 ,  C07K16/18 ,  A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/18 ,  A61K38/00 ,  C07K2317/24

    摘要： The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.

    摘要翻译： 本发明涉及在体内形成的晚期糖基化终产物的单克隆抗体和与体外形成的晚期糖基化终产物交叉反应的单克隆抗体以及基于其的诊断和治疗方法。 更具体地，本发明涉及与体内产生的晚期糖基化终产物（AGE）反应的单克隆抗体或其抗原结合片段，其单克隆抗体或其抗原结合片段表现出单克隆抗体4G9的免疫结合特征， 由保藏在美国典型培养物保藏中心（ATCC）并分配保藏号CRL 11626的杂交瘤4G9产生。在具体实施方案中，将4G9抗体用于夹心ELISA中以检测ApoB-AGE，IgG-AGE，胶原-AGE， 血清AGE肽和蛋白质和尿AGE肽和蛋白质。